Gamida Cell CEO Dr. Yael Margolin said, "The NiCord study is a first step in broadening Gamida Cell's pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need." SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a ... (more)
http://technews.tmcnet.com/news/2012/11/12/6717099.htm
http://technews.tmcnet.com/news/2012/11/12/6717099.htm
No comments:
Post a Comment